Summary
Pfizer Inc. reported total revenues of $13.5 billion for the first quarter of 2013, a decrease of 9% compared to the same period in 2012. This decline was primarily driven by the loss of exclusivity for key products like Lipitor, leading to a significant drop in branded revenue. Despite the revenue challenges, Pfizer demonstrated strong operational execution, with income from continuing operations increasing by 60% to $2.8 billion, mainly due to favorable legal settlements and lower restructuring charges compared to the prior year. The company also made significant progress in its strategic initiatives, including the initial public offering (IPO) of its Animal Health subsidiary, Zoetis, and the sale of its Nutrition business, which are expected to streamline its portfolio and focus on core biopharmaceutical operations. The company's financial performance in Q1 2013 was marked by a significant decrease in revenues, largely due to patent expirations and generic competition impacting major products such as Lipitor. However, profitability improved substantially year-over-year, driven by reduced operating expenses, lower restructuring charges, and a favorable legal settlement. The strategic divestiture of the Nutrition business and the partial IPO of Zoetis represent key steps in Pfizer's ongoing transformation, aiming to create a more focused biopharmaceutical company. Investors should monitor the impact of ongoing product exclusivity losses and the company's ability to drive growth from its pipeline and newer products.
Financial Highlights
53 data points| Revenue | $12.41B |
| Cost of Revenue | $2.26B |
| Gross Profit | $10.15B |
| SG&A Expenses | $3.22B |
| Operating Income | $2.61B |
| Interest Expense | $371.00M |
| Net Income | $2.75B |
| EPS (Basic) | $0.38 |
| EPS (Diluted) | $0.38 |
| Shares Outstanding (Basic) | 7.19B |
| Shares Outstanding (Diluted) | 7.27B |
Key Highlights
- 1Total revenues decreased by 9% to $13.5 billion, primarily due to product losses of exclusivity (e.g., Lipitor).
- 2Income from continuing operations increased by 60% to $2.8 billion, driven by lower costs and favorable legal settlements.
- 3Diluted earnings per share (EPS) increased to $0.38 from $0.24 in the prior year's quarter.
- 4The company completed the IPO of its Animal Health subsidiary, Zoetis, selling approximately 19.8% of its shares.
- 5Significant cost reductions were achieved through ongoing productivity initiatives and workforce reductions.
- 6Research and Development (R&D) expenses decreased by 13% due to program discontinuations and cost savings.
- 7The company repurchased approximately $4.6 billion of its common stock during the quarter.